Switch theme
Sign up to access all valuation multiples
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
1998
1.0K+
LTM Revenue $1.2B
LTM EBITDA $242M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PTC Therapeutics has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $242M.
In the most recent fiscal year, PTC Therapeutics achieved revenue of $807M and an EBITDA of -$120M.
PTC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PTC Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $807M | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $749M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $242M | XXX | -$120M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | -15% | XXX | XXX | XXX |
| EBIT | $177M | XXX | -$147M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | -18% | XXX | XXX | XXX |
| Net Profit | $56.9M | XXX | -$363M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | -45% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.6B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PTC Therapeutics's stock price is $49.
PTC Therapeutics has current market cap of $3.8B, and EV of $2.2B.
See PTC Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $3.8B | XXX | XXX | XXX | XXX | $0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PTC Therapeutics has market cap of $3.8B and EV of $2.2B.
PTC Therapeutics's trades at 2.7x EV/Revenue multiple, and -18.3x EV/EBITDA.
Equity research analysts estimate PTC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PTC Therapeutics has a P/E ratio of 67.6x.
See valuation multiples for PTC Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.8B | XXX | $3.8B | XXX | XXX | XXX |
| EV (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.1x | XXX | -18.3x | XXX | XXX | XXX |
| EV/EBIT | 12.5x | XXX | -15.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 67.6x | XXX | -10.6x | XXX | XXX | XXX |
| EV/FCF | 9.3x | XXX | -12.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPTC Therapeutics's last 12 month revenue growth is 15%
PTC Therapeutics's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.9M for the same period.
PTC Therapeutics's rule of 40 is -20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PTC Therapeutics's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PTC Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | -15% | XXX | XXX | XXX |
| EBITDA Growth | 122% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -20% | XXX | 0% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 111% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PTC Therapeutics acquired XXX companies to date.
Last acquisition by PTC Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . PTC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PTC Therapeutics founded? | PTC Therapeutics was founded in 1998. |
| Where is PTC Therapeutics headquartered? | PTC Therapeutics is headquartered in United States of America. |
| How many employees does PTC Therapeutics have? | As of today, PTC Therapeutics has 1.0K+ employees. |
| Who is the CEO of PTC Therapeutics? | PTC Therapeutics's CEO is Dr. Matthew B. Klein, F.A.C.S.,M.D.,M.S.. |
| Is PTC Therapeutics publicy listed? | Yes, PTC Therapeutics is a public company listed on NAS. |
| What is the stock symbol of PTC Therapeutics? | PTC Therapeutics trades under PTCT ticker. |
| When did PTC Therapeutics go public? | PTC Therapeutics went public in 2013. |
| Who are competitors of PTC Therapeutics? | Similar companies to PTC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PTC Therapeutics? | PTC Therapeutics's current market cap is $3.8B |
| What is the current revenue of PTC Therapeutics? | PTC Therapeutics's last 12 months revenue is $1.2B. |
| What is the current revenue growth of PTC Therapeutics? | PTC Therapeutics revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of PTC Therapeutics? | Current revenue multiple of PTC Therapeutics is 1.8x. |
| Is PTC Therapeutics profitable? | Yes, PTC Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PTC Therapeutics? | PTC Therapeutics's last 12 months EBITDA is $242M. |
| What is PTC Therapeutics's EBITDA margin? | PTC Therapeutics's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of PTC Therapeutics? | Current EBITDA multiple of PTC Therapeutics is 9.1x. |
| What is the current FCF of PTC Therapeutics? | PTC Therapeutics's last 12 months FCF is $237M. |
| What is PTC Therapeutics's FCF margin? | PTC Therapeutics's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of PTC Therapeutics? | Current FCF multiple of PTC Therapeutics is 9.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
